Clinical trials: Radiotherapy
Prostate Cancer
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce…
- Trial name
- NCT06496256
- Testing
- Barrigel, Transrectal Ultrasound
- Where
- 13 sites in United States, Australia
- Volunteers
- 84 people
- Sponsor
- Palette Life Sciences, Inc.
Glioblastoma Multiforme
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Immunotoxin therapy may be effective in treating malignant glioma. Immunotoxins can locate tumor cells and kill them without harming normal cells.
- Trial name
- NCT00104091
- Testing
- TP-38
- Volunteers
- 56 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Neoplasms, Breast
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain…
- Trial name
- NCT00263588
- Testing
- lapatinib
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent High-grade Glioma, Recurrent Glioblastoma
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
This is a multi-centered, radiation dose escalation, open, exploratory, Phase 1/2a clinical trial on the safety, efficacy and pharmacokinetic characteristics of BNCT in patients with recurrent high-grade gliomas.
- Conditions
- Recurrent High-grade Glioma, Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligodendroglioma
- Trial name
- NCT05737212
- Testing
- 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Dawonmedax Co., Ltd.
Prostate Cancer
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
The purpose of this study is to test a novel diagnostic Positron Emission Tomography (PET) imaging agent for safety and biodistribution.
- Trial name
- NCT02916537
- Testing
- CTT1057, Prostatectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cancer Targeted Technology
Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer.
- Trial name
- NCT01644669
- Testing
- Intra-operative Radiation Therapy - IORT
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Xoft, Inc.
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Trial name
- NCT02405585
- Testing
- mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- NewLink Genetics Corporation
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or…
- Trial name
- NCT04429191
- Testing
- Humanized anti-CD117 Monoclonal Antibody (JSP191)
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jasper Therapeutics, Inc.
Advanced Cancer
DM-CHOC-PEN Plus Radiation for Brain Tumors
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT03371004
- Testing
- 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- DEKK-TEC, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors
RATIONALE: Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00091052
- Testing
- sargramostim, radiation therapy
- Where
- United States
- Sponsor
- Sirius Medicine
Coronary Artery Disease
A Multicenter Trial of Localized Radiation Therapy to Inhibit Restenosis (GAMMA V)
The objectives of this study are: 1. To show a reduction in the late thrombosis (LT) rate following percutaneous revascularization using current interventional techniques with new stent placement and intravascular radiation…
- Trial name
- NCT00232778
- Testing
- GAMMA-Iridium-192 catheter
- Volunteers
- 579 people
- Sponsor
- Cordis US Corp.
Prostate Cancer, Recurrent Prostate Cancer
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer
This is a multi-center clinical study enrolling up to 12 participants . The primary objective of the study is to evaluate the safety of Alpha DaRT for the treatment of locally recurrent prostate cancer .
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Locally Recurrent Prostate Cancer
- Trial name
- NCT07290998
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Volunteers
- 12 people
- Sponsor
- Alpha Tau Medical LTD.
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
Chronic Radiation Ulcer
Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer
The goal of this clinical trial is to learn if drug Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (PEP-TISSEEL) works to treat chronic radiation ulcer in adults and compare it with comparator TISSEEL.
- Trial name
- NCT06793748
- Testing
- PEP-TISSEEL, TISSEEL Fibrin Sealant KIT
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Rion Inc.
Prostate Cancer
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
The primary objective of the study was to compare the efficacy of brachytherapy versus brachytherapy + triptorelin 22.5 mg (single injection) in subjects with recurrence of prostate cancer previously treated with radiotherapy.
- Trial name
- ANABRAQ (NCT01374087)
- Testing
- Triptorelin 22.5 mg, Brachytherapy
- Where
- 11 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Ipsen
Metastatic Brain Tumors, Progression
Laser Ablation After Stereotactic Radiosurgery
The need for new technologies and devices in the field of neurosurgery is well established. In April 2013, FDA cleared NeuroBlate™ System, minimally invasive robotic laser thermotherapy tool.
- Conditions
- Metastatic Brain Tumors, Progression, Radiation Necrosis, Quality of Life
- Trial name
- LAASR (NCT01651078)
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Monteris Medical
Acute Radiation Syndrome
Safety and Pharmacokinetic Study of BIO 300 Capsules
This trial is designed to evaluate the safety and pharmacokinetics of BIO 300 capsules when administered orally to healthy male and female volunteers. BIO 300 is expected to be safe for use starting at 500 mg.
- Trial name
- NCT00504335
- Testing
- BIO 300 Capsules
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Humanetics Corporation
Radiation-Induced Mucositis, Head and Neck Cancer
Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)
The aim of the present study is to collect data on the feasibility of a preventative/therapeutic approach of radiation-induced oral mucositis with benzydamine oromucosal solution (mouthwash) in patients with head and neck cancer.
- Trial name
- BOOM (NCT05055726)
- Testing
- Benzydamine Hydrochloride 0.15% w/v oromucosal solution
- Where
- 10 sites in Hungary, Poland
- Volunteers
- 100 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Breast Cancer
Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB
To determine local disease control (recurrence) with shorter course of APBI delivered with a breast brachytherapy applicator.
- Trial name
- NCT01072838
- Testing
- APBI (Dose Escalation), Contura MLB Breast Brachytherapy Catheter
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- SenoRx, Inc.